Using antibiotics in suspected haemolytic-uraemic syndrome

BMJ

Volumn 330, Issue 7501, 2005, Pages 1209-

  Dundas, Stephanie ^a   Todd, W T Andrew ^a   Neill, Marguerite A ^b   Tarr, Phillip I ^c  

^a MONKLANDS HOSPITAL   (United Kingdom)

^b BROWN UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; D DIMER; FIBRINOGEN; FOSFOMYCIN; HEMOGLOBIN; PROTHROMBIN; THROMBOSPONDIN;

ANTIBIOTIC THERAPY; BLOOD CLOTTING DISORDER; DRUG SAFETY; ENTEROBACTER INFECTION; ESCHERICHIA COLI O157; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SEPSIS; THROMBOCYTOPENIA;

ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI O157; HEMOLYTIC-UREMIC SYNDROME; HUMANS;

EID: 85007685353     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.330.7501.1209     Document Type: Letter

References (3)

1. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002; 288: 996–1001.
2. Phillips B, Tyerman K, Whiteley SM. Use of antibiotics in suspected haemolytic-uraemic syndrome. BMJ 2005; 330: 409–10. (19 February.)
3. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999; 52: 357–62.